Vaccination against HPV is not profitable in the Netherlands, study shows

Even under favorable conditions, including protection against 70 percent of cervical cancers and no side effects, vaccination against human papillomavirus is not profitable in the Netherlands, a study published online July 1 in the Journal of the National Cancer Institute.The researchers conducted the study because of the cost-effectiveness of HPV vaccination may be limited by the small number of cases of cervical cancer and deaths in the region associated with the current screening program of the Dutch cervical cancer ‘ the uterus.

In the study, Inge M.M. de Kok, Department of Public Health at the Erasmus MC, University Medical Center in Rotterdam, the Netherlands, and colleagues estimated the costs and effects of adding HPV vaccination against the current program using a model microsimulation screening analysis.

In the study, researchers examined the records of deaths 1905-2005 in California to see if there was a statistical relationship between initials and longevity.

This entry was posted in institution. Bookmark the permalink.

Comments are closed.